<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645317</url>
  </required_header>
  <id_info>
    <org_study_id>M401</org_study_id>
    <nct_id>NCT03645317</nct_id>
  </id_info>
  <brief_title>Avoiding Cardiac Toxicity in Lung Cancer Patients Treated With Curative-intent Radiotherapy</brief_title>
  <acronym>ACCOLADE</acronym>
  <official_title>A Study Investigating How to Avoid Cardiac Toxicity in Lung Cancer Patients Treated With Curative-intent Radiotherapy to Improve Survival, Funded by Yorkshire Cancer Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elizabeth Craven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Christie NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy plays a major role in the treatment of lung cancer and recent advances in
      radiotherapy have led to better cure rates. However, the radiotherapy dose needed to destroy
      the cancer cells can unfortunately also damage the surrounding organs, such as the heart. The
      precise mechanism of damage and which areas of the heart are more sensitive to radiation is
      not currently known. This project uses the analysis of large amounts of existing radiotherapy
      treatment data to determine this. Establishing detailed radiotherapy dose limits for the
      heart and the heart's sub-structures will lead to the delivery of heart-sparing radiotherapy,
      where possible, in lung cancer patients treated in Yorkshire and Greater Manchester. The
      investigators estimate that this should lead to an improvement in one-year survival of
      approximately 10%.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of radiation dose to the heart assessed using blood test (full blood count)</measure>
    <time_frame>4 months (duration of each participant on study)</time_frame>
    <description>The effect of radiation dose to the heart assessed using full blood count measurement at the following time points (before radiotherapy, within 7 days post-radiotherapy and at 4 months post-radiotherapy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of radiation dose to the heart assessed using blood test (lipids &amp; cholesterol - LDL &amp; HDL levels)</measure>
    <time_frame>4 months (duration of each participant on study)</time_frame>
    <description>The effect of radiation dose to the heart assessed using lipid &amp; cholesterol (LDL &amp; HDL) measurements at the following time points (before radiotherapy, within 7 days post-radiotherapy and at 4 months post-radiotherapy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of radiation dose to the heart assessed using blood test (troponin)</measure>
    <time_frame>4 months (duration of each participant on study)</time_frame>
    <description>The effect of radiation dose to the heart assessed using troponin measurement at the following time points (before radiotherapy, within 7 days post-radiotherapy and at 4 months post-radiotherapy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of radiation dose to the heart assessed using blood test (C-reactive protein)</measure>
    <time_frame>4 months (duration of each participant on study)</time_frame>
    <description>The effect of radiation dose to the heart assessed using C-reactive protein measurement at the following time points (before radiotherapy, within 7 days post-radiotherapy and at 4 months post-radiotherapy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of radiation dose to the heart assessed using blood test (brain natriuretic peptide)</measure>
    <time_frame>4 months (duration of each participant on study)</time_frame>
    <description>The effect of radiation dose to the heart assessed using brain natriuretic peptide measurement at the following time points (before radiotherapy, within 7 days post-radiotherapy and at 4 months post-radiotherapy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of radiation dose to the heart assessed using cardiac imaging (cardiac ultrasound)</measure>
    <time_frame>4 months (duration of each participant on study)</time_frame>
    <description>The effect of radiation dose to the heart assessed using cardiac ultrasound scans at the following time points (before radiotherapy and at 4 months after radiotherapy). The following components of the cardiac ultrasound measured during the study: parasternal long axis, parasternal short axis, apical 2/4/5 chambers, apical long axis, subcostal and parasternal notch.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of radiation dose to the heart assessed using cardiac imaging (cardiac CT)</measure>
    <time_frame>4 months (duration of each participant on study)</time_frame>
    <description>The effect of radiation dose to the heart assessed using cardiac CT scans at the following time points (before radiotherapy and at 4 months after radiotherapy). The following components of the cardiac CT scan measured during the study: coronary calcium score (Agaston/Volume) - CAC-RDS 0, CAC-RDS 1, CAC-RDS 2, CAC-RDS 3, CAC-RADS classification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of radiation dose to the heart assessed using cardiac imaging (12-lead ECG)</measure>
    <time_frame>4 months (duration of each participant on study)</time_frame>
    <description>The effect of radiation dose to the heart assessed using 12-lead ECG at the following time points (before radiotherapy and at 4 months after radiotherapy). The following components of the ECG measured during the study: heart rate, rhythm, P wave, QRS complex, QT interval, ST segment &amp; PR interval.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood samples (FBC, lipids, cholesterol, troponin, CRP, BNP) Cardiac imaging (cardiac CT, cardiac ultrasound, 12-lead ECG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood tests &amp; cardiac imaging</intervention_name>
    <description>Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or clinical diagnosis of lung cancer (Stage I-III non-small cell and
             small cell lung cancer) suitable for curative-intent radiotherapy

          -  Patients suitable for curative-intent radiotherapy (minimum 20 fractions for
             conventional fractionation and 3-8 fractions for SABR)

          -  Life expectancy &gt; 4 months

          -  Age â‰¥ 18 years

          -  Patient has read and understood the participant information sheet and given informed
             consent

        Exclusion criteria:

          -  No histological or clinical diagnosis of lung cancer (Stage I-III non-small cell and
             small cell lung cancer) and not suitable for curative-intent radiotherapy

          -  Patients not suitable for curative-intent radiotherapy (minimum 20 fractions for
             conventional fractionation and 3-8 fractions for SABR)

          -  Life expectancy &lt; 4 months

          -  Age &lt; 18 years

          -  Patient has not read and understood the participant information sheet and has not
             given informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Faivre-Finn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie NHS Foundation Trust / Univerrsity of Manchester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne Faivre-Finn, PhD</last_name>
    <phone>0044 (0)161 446 8200</phone>
    <phone_ext>8200</phone_ext>
    <email>corinne.finn@christie.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Craven, MSc</last_name>
    <phone>0161 446 3045</phone>
    <email>elizabeth.craven@manchester.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Craven, MSc</last_name>
      <phone>0161 446 3045</phone>
      <email>Elizabeth.Craven@machester.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Kevin Franks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Craven, MSc</last_name>
      <phone>0161 446 3045</phone>
      <email>elizabeth.craven@manchester.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Corinne Faivre-Finn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Christie NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Elizabeth Craven</investigator_full_name>
    <investigator_title>Research Project Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans to share data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

